Ocedurenone

Ocedurenone
Clinical data
Other names	KBP-5074
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(3S,3aR)-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile;
CAS Number	1359969-24-6 ;
PubChem CID	75593324 ;
UNII	L46509378R ;
Chemical and physical data
Formula	C28H30ClN5O2
Molar mass	504.03 g·mol−1

Last updated September 13, 2025

Ocedurenone, formerly known as KBP-5074,^[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.^[2]^[3] In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.^[4]^[5]

References

↑ "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.
↑ Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi: 10.1080/13543784.2021.1985462 . ISSN 1744-7658. PMID 34595995.
↑ Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073 . PMC 8189259 . PMID 33966452.
↑ "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. 16 October 2023. Retrieved 4 November 2023.
↑ "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.

[2] Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi: 10.1080/13543784.2021.1985462 . ISSN 1744-7658. PMID 34595995.

[3] Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073 . PMC 8189259 . PMID 33966452.

[4] "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. 16 October 2023. Retrieved 4 November 2023.

[5] "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.

[1]

[2]

[3]

[4]

[5]